Contraception in Women With Medical Comorbidities: Clinical Risk Stratification and Individualized Therapeutic Strategies

Women of reproductive age increasingly present with chronic medical conditions that significantly influence contraceptive safety and effectiveness. Hormonal contraceptives, particularly estrogen-containing formulations, exert systemic effects on coagulation pathways, vascular tone, blood pressure regulation, and metabolic function. These mechanisms contribute to an increased risk of venous thromboembolism, hypertension, and cardiovascular events in susceptible populations, especially in women with obesity, diabetes mellitus, dyslipidemia, autoimmune disorders, or pre-existing cardiovascular disease. Progestin-only methods generally demonstrate a lower thrombotic risk profile; however, their metabolic and systemic effects vary depending on the specific formulation. Long-acting reversible contraceptives, including levonorgestrel-releasing and copper intrauterine devices, offer highly effective options with minimal systemic impact and are frequently recommended for women with contraindications to estrogen. Comorbid conditions such as systemic lupus erythematosus, antiphospholipid syndrome, chronic liver disease, chronic kidney disease, and hormone-sensitive malignancies further complicate contraceptive decision-making. In these settings, individualized risk assessment must consider organ-specific vulnerability, disease activity, and potential drug-drug interactions, particularly with enzyme-inducing medications or immunosuppressive therapies. Evidence-based eligibility classification systems provide structured guidance for identifying absolute and relative contraindications and support consistent clinical practice. Effective contraceptive care in medically complex patients requires multidisciplinary collaboration, shared decision-making, and reproductive life planning. Comprehensive counseling, regular monitoring, and timely method adjustment are essential to reduce unintended pregnancies, prevent disease exacerbation, and minimize maternal morbidity. Ultimately, tailored contraceptive strategies that integrate pathophysiological understanding with patient-centered care are critical to optimizing reproductive and overall health outcomes in women with comorbidities.